The measurement of thoron in the breath of dogs administered inhaled or injected ThO 2 .
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
An epidemiological follow-up study was conducted on 272 Thorotrast-administered war-wounded ex-servicemen to determine their status as of 31 December 1980, after a lapse of 35-43 yr from Thorotrast injection. In the 251 cases who had been intravascularly injected with Thorotrast in the past, 40 malignant hepatic tumors, 3 blood diseases, 2 lung cancers, 1 osteosarcoma, 22 other malignant tumors, and 13 cases of liver cirrhosis were found. The mortality rates due to hepatic and other malignant tumors, blood diseases, and cirrhosis of the liver as well as the overall mortality rate were significantly higher in the intravascular-Thorotrast group than in the controls. In the remaining 21 cases, who had been given Thorotrast by a route other than intravascularly, none of the deaths was found to be related to Thorotrast administration.
The absorbed dose in the liver, spleen and bone marrow of Thorotrast patients was estimated for 71 autopsy cases. 232Th amounts in tissues were determined from measurements of 228Ac gamma-rays and the activity ratio of 228Ac to 232Th. In calculating the absorbed dose, Kaul's data were used as values of the steady state activity ratio between 232Th and its daughters and the self-absorption of alpha-rays in Thorotrast aggregates. The autopsy cases in which the cumulative dose was estimated consisted of 45 cases of malignant hepatic tumor, 12 cases of liver cirrhosis, 7 cases of blood disease and 7 cases of other diseases. The estimated absorbed doses in the organs were presented and the relationship between the dose and radiation effects on organ tissues was discussed.
In 193 cases autopsied between 1945 and 1980, all persons who had been intravascularly injected with Thorotrast in life, the authors found 131 malignant hepatic tumors, 20 liver cirrhoses, 6 myeloid leukemias, 4 erythroleukemias, 5 aplastic anemias, 4 lung cancers, 1 mesothelioma and 1 osteosarcoma. The causes of death in the Thorotrast-administered autopsy group (193 cases) were compared with those of a non-Thorotrast-administered autopsy group (95,000 cases) of the same sex and age at death as recorded in the Annals of Japanese Pathological Autopsy cases from 1958 to 1978. This comparison revealed that the frequencies of malignant hepatic tumors, liver cirrhosis, erythroleukemia, and aplastic anemia were significantly higher in the Thorotrast-administered group than in the non-Thorotrast-administered group.